RhinoMAP Diagnostic Platform Validation
Chronic Respiratory Diseases (Asthma, COPD, Chronic Sinusitis)
Pre-clinicalActive
Key Facts
Indication
Chronic Respiratory Diseases (Asthma, COPD, Chronic Sinusitis)
Phase
Pre-clinical
Status
Active
Company
About Diag-Nose.io
Diag-Nose.io is a private, clinical-stage biotech company pioneering AI-driven precision diagnostics for chronic respiratory diseases. Founded in 2020 by a Stanford-based team, the company has developed the RhinoMAP platform, which uses nasal liquid biopsies to generate proteomic biomarker profiles, aiming to predict treatment response and guide therapy. The company is pre-revenue, having closed an oversubscribed $3.15M seed round in early 2025, and is actively recruiting patients for its clinical studies to validate its platform. Its long-term vision is to both improve patient outcomes through precise diagnostics and discover novel therapeutic targets.
View full company profile